Our Therapies

The first and only FDA-approved
treatment for Demodex blepharitis

Careers

Publications

Efficacy and Safety of Lotilaner Ophthalmic Solution 0.25% for the Treatment of Demodex Blepharitis: A Meta-Analysis of Randomized Controlled Trials

View Article

The Impact of Demodex Blepharitis on Patient Symptoms and Daily Life

View Article

Efficacy and Safety of Lotilaner Ophthalmic Solution 0.25% in the Treatment of Demodex Blepharitis: A Systematic Review and Meta-Analysis

View Article

A Systematic Review and Meta-Analysis of the Safety and Efficacy of 0.25% Lotilaner Ophthalmic Solution in the Treatment of Demodex Blepharitis

View Article

Lotilaner Ophthalmic Solution 0.25%: First Approval

View Article

Lotilaner Ophthalmic Solution 0.25% for Demodex Blepharitis: Randomized, Vehicle-Controlled, Multicenter, Phase 3 Trial (Saturn-2)

View Article

Demodex Blepharitis: A Comprehensive Review of the Disease, Current Management, and Emerging Therapies

View Article

Lotilaner Ophthalmic Solution, 0.25%, for the Treatment of Demodex Blepharitis: Results of a Prospective, Randomized, Vehicle-Controlled, Double-Masked, Pivotal Trial (Saturn-1)

View Article

Clinical Diagnosis and Management of Demodex Blepharitis: The Demodex Expert Panel on Treatment and Eyelid Health (DEPTH)

View Article

Delphi Panel Consensus Regarding Current Clinical Practice Management Options for Demodex Blepharitis

View Article

Our Terms of Use and Privacy Policy have changed.

By clicking accept, you agree that you have read and will abide by these new terms.